Role of Genetic Polymorphisms in the Angiogenesis Pathway and Non-small-Cell Lung Cancer Tumor Behavior: Implications in Risk Assessment and Clinical Outcome

摘要: Lung cancer is a highly prevalent disease worldwide. Currently, it the leading cause of cancer-related deaths in Western nations. Non-small-cell lung (NSCLC) corresponds to approximately 85% all histological types. Risk factors are usually associated with tobacco consumption, occupational exposure, radon, and passive smoking. diagnosis often occurs advanced stages IIIB IV. Thus systemic therapies, such as cytotoxic agents therapeutic targets, play major role NSCLC management. To date, many influence behavior and, therefore, clinical response epidermal growth factor (EGF) its receptor (EGFR) vascular endothelial (VEGF) (VEGFR). Angiogenesis-related genetic polymorphisms primary interest research. Recently, Portuguese study identified EGF +61 A/G polymorphism risk for patients cancer. Furthermore, other polymorphisms, VEGF −2578 C/A −1154 G/A, were correlated increased tumor expression, density, poor survival. This topic will address research involving angiogenesis behavior.